Literature DB >> 20693298

Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

K D Swenerton1, J L Santos, C B Gilks, M Köbel, P J Hoskins, F Wong, N D Le.   

Abstract

BACKGROUND: To explore the influence of ovarian cancer histotype on the effectiveness of adjuvant radiotherapy (RT).
METHODS: A review of a population-based experience included all referred women with no reported macroscopic residuum following primary surgery who underwent adjuvant platin-based chemotherapy (CT), with or without sequential RT, and for whom it was possible to assign histotype according to the contemporary criteria.
RESULTS: Seven hundred and three subjects were eligible, of these 351 received RT. For those with apparent stage I and II tumors, the cohort with clear cell (C), endometrioid (E), and mucinous (M) disease who additionally received RT exhibited a 40% reduction in disease-specific mortality and a 43% reduction in overall mortality.
CONCLUSIONS: The curability of those with stage I and II C-, E-, and M-type ovarian carcinomas was enhanced by RT-containing adjuvant therapy. This benefit did not extend to those with stage III or serous tumors. These findings necessitate reassessments of the role of RT and of the nonselective surgical and CT approaches that have characterized ovarian cancer care.

Entities:  

Mesh:

Year:  2010        PMID: 20693298      PMCID: PMC3030466          DOI: 10.1093/annonc/mdq383

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

1.  'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation.

Authors:  P.J. Hoskins; K.D. Swenerton; M. Manji; F. Wong; S.E. O'Reilly; E.J. McMurtrie; N. Le; B. Acker; J. Le Richer
Journal:  Int J Gynecol Cancer       Date:  1994-07       Impact factor: 3.437

2.  Summary and discussion of session recommendations.

Authors:  Jane Fountain; Edward Trimble; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2006-10-05       Impact factor: 5.482

3.  The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.

Authors:  Masashi Takano; Toru Sugiyama; Nobuo Yaegashi; Mitsuaki Suzuki; Hiroshi Tsuda; Satoru Sagae; Yasuhiro Udagawa; Kazuo Kuzuya; Junzo Kigawa; Satoshi Takeuchi; Hitoshi Tsuda; Takuya Moriya; Yoshihiro Kikuchi
Journal:  Int J Gynecol Cancer       Date:  2009-11       Impact factor: 3.437

4.  Lymph node metastasis in stage I epithelial ovarian cancer.

Authors:  M Suzuki; M Ohwada; T Yamada; T Kohno; I Sekiguchi; I Sato
Journal:  Gynecol Oncol       Date:  2000-11       Impact factor: 5.482

5.  Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy.

Authors:  P J Hoskins; S E O'Reilly; K D Swenerton; J J Spinelli; R N Fairey; J L Benedet
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

6.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

Authors:  C Blake Gilks; Diana N Ionescu; Steve E Kalloger; Martin Köbel; Julie Irving; Blaise Clarke; Jennifer Santos; Nhu Le; Veronika Moravan; Kenneth Swenerton
Journal:  Hum Pathol       Date:  2008-07-07       Impact factor: 3.466

7.  Prognostic factors in patients with stage I epithelial ovarian cancer.

Authors:  A J Dembo; M Davy; A E Stenwig; E J Berle; R S Bush; K Kjorstad
Journal:  Obstet Gynecol       Date:  1990-02       Impact factor: 7.661

Review 8.  Prognostic indices in ovarian cancer. Their significance in treatment planning.

Authors:  K D Swenerton
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1992

9.  Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

Authors:  Lan Huang; Kathleen A Cronin; Karen A Johnson; Angela B Mariotto; Eric J Feuer
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

10.  Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.

Authors:  K Fujiwara; S Suzuki; E Yoden; H Ishikawa; Y Imajo; I Kohno
Journal:  Int J Gynecol Cancer       Date:  2002 May-Jun       Impact factor: 3.437

View more
  12 in total

Review 1.  Clear cell carcinoma of ovary and uterus.

Authors:  Rosalind M Glasspool; Iain A McNeish
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

3.  Treatment-interval associated effect of irradiation on locoregionally-relapsed ovarian cancer.

Authors:  Motoaki Saito; Chihiro Kanehira; Seiji Isonishi
Journal:  Mol Clin Oncol       Date:  2014-06-16

4.  Type-specific cell line models for type-specific ovarian cancer research.

Authors:  Michael S Anglesio; Kimberly C Wiegand; Nataliya Melnyk; Christine Chow; Clara Salamanca; Leah M Prentice; Janine Senz; Winnie Yang; Monique A Spillman; Dawn R Cochrane; Karey Shumansky; Sohrab P Shah; Steve E Kalloger; David G Huntsman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

5.  Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011.

Authors:  Sagar C Patel; Jonathan Frandsen; Sudershan Bhatia; David Gaffney
Journal:  J Gynecol Oncol       Date:  2016-05-03       Impact factor: 4.401

Review 6.  Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.

Authors:  Emma C Fields; William P McGuire; Lilie Lin; Sarah M Temkin
Journal:  Front Oncol       Date:  2017-08-21       Impact factor: 6.244

7.  Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment.

Authors:  Noorie Choi; Ji Hyun Chang; Suzy Kim; Hak Jae Kim
Journal:  Radiat Oncol J       Date:  2017-06-30

8.  Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Authors:  Peter F Rambau; Robert A Vierkant; Maria P Intermaggio; Linda E Kelemen; Marc T Goodman; Esther Herpel; Paul D Pharoah; Stefan Kommoss; Mercedes Jimenez-Linan; Beth Y Karlan; Aleksandra Gentry-Maharaj; Usha Menon; Susanna Hernando Polo; Francisco J Candido Dos Reis; Jennifer Anne Doherty; Simon A Gayther; Raghwa Sharma; Melissa C Larson; Paul R Harnett; Emma Hatfield; Jurandyr M de Andrade; Gregg S Nelson; Helen Steed; Joellen M Schildkraut; Micheal E Carney; Estrid Høgdall; Alice S Whittemore; Martin Widschwendter; Catherine J Kennedy; Frances Wang; Qin Wang; Chen Wang; Sebastian M Armasu; Frances Daley; Penny Coulson; Micheal E Jones; Micheal S Anglesio; Christine Chow; Anna de Fazio; Montserrat García-Closas; Sara Y Brucker; Cezary Cybulski; Holly R Harris; Andreas D Hartkopf; Tomasz Huzarski; Allan Jensen; Jan Lubiński; Oleg Oszurek; Javier Benitez; Fady Mina; Annette Staebler; Florin Andrei Taran; Jana Pasternak; Aline Talhouk; Mary Anne Rossing; Joy Hendley; Robert P Edwards; Sian Fereday; Francesmary Modugno; Roberta B Ness; Weiva Sieh; Mona A El-Bahrawy; Stacey J Winham; Jenny Lester; Susanne K Kjaer; Jacek Gronwald; Peter Sinn; Peter A Fasching; Jenny Chang-Claude; Kirsten B Moysich; David D Bowtell; Brenda Y Hernandez; Hugh Luk; Sabine Behrens; Mitul Shah; Audrey Jung; Prafull Ghatage; Jennifer Alsop; Kathryn Alsop; Jesús García-Donas; Pamela J Thompson; Anthony J Swerdlow; Chloe Karpinskyj; Alicia Cazorla-Jiménez; María J García; Susha Deen; Lynne R Wilkens; José Palacios; Andrew Berchuck; Jennifer M Koziak; James D Brenton; Linda S Cook; Ellen L Goode; David G Huntsman; Susan J Ramus; Martin Köbel
Journal:  J Pathol Clin Res       Date:  2018-09-21

9.  Patterns of spread of clear cell ovarian cancer: Case report and case series.

Authors:  Aalok Kumar; C Blake Gilks; Colin Mar; Jennifer Santos; Anna V Tinker
Journal:  Gynecol Oncol Case Rep       Date:  2013-08-03

10.  Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma.

Authors:  Huidi Liu; Zheng Zeng; Mitra Afsharpad; Caiji Lin; Siwen Wang; Hao Yang; Shuhong Liu; Linda E Kelemen; Wenwen Xu; Wenqing Ma; Qian Xiang; Emilio Mastriani; Pengfei Wang; Jiali Wang; Shu-Lin Liu; Randal N Johnston; Martin Köbel
Journal:  Front Oncol       Date:  2020-01-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.